Delta-Fly Pharma, Inc. (TYO:4598)
Japan · Delayed Price · Currency is JPY 99.00
-1.00 (-1.00%)
Oct 9, 2026, 3:30 PM JST
Delta-Fly Pharma Market Cap
Delta-Fly Pharma has a market cap or net worth of 1.46 billion as of October 9, 2026. It is the 42,113th most valuable company in the world and the 3,818th biggest in Japan. Its market cap has decreased by 71.89% in one year.
Market Cap
1.46B
Enterprise Value
1.38B
Revenue
n/a
Global Rank
Country Rank
#3,818 Japan
PE Ratio
n/a
ChartMarket Cap Chart
Since October 12, 2018, Delta-Fly Pharma's market cap has decreased from 21.91B to 1.46B, a decrease of -93.32%. That is a compound annual growth rate of -28.71%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 9, 2026 | 1.46B | -76.41% |
| Dec 30, 2025 | 6.20B | 18.44% |
| Dec 30, 2024 | 5.24B | -37.32% |
| Dec 29, 2023 | 8.35B | 21.17% |
| Dec 30, 2022 | 6.89B | -14.46% |
| Dec 30, 2021 | 8.06B | 49.71% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 12, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Noile-Immune Biotech | 4.43B |
| Chordia Therapeutics | 4.40B |
| Kohjin Bio | 4.17B |
| D. Western Therapeutics Institute | 4.03B |
| Ribomic | 4.01B |
| Transgenic Group | 3.90B |
| Human Metabolome Technologies | 3.36B |
| Modalis Therapeutics | 3.19B |